Dr. Reddy's Laboratories Cash Flow - Quarterly (NYSE:RDY)

Add to My Stocks
$33.83 $0.52 (1.56%) RDY stock closing price Aug 17, 2018 (Closing)

For analyzing any company like Dr. Reddy's Laboratories from an investment perspective, its important to check the cash flow statement. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Dr. Reddy's Laboratories profits and Dr. Reddy's Laboratories debt. Dr. Reddy's Laboratories stock analysis shows positive net income cash flow of $67M till 2019 Q1. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Dr. Reddy's Laboratories has a negative cash and cash equivalents change of $-5M.

View and download details of Dr. Reddy's Laboratories cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Apr - Mar2019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow44M180M136M88M43M174M124M83M40M155M
Net Increase (Decrease) in Assets Liabilities-185M-138M-108M-91M-86M-83M-98M-42M5M-3M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2M84M57M21M2M54M36M11M13M168M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-29M-141M-121M-84M-43M-188M-136M-95M-48M-180M
Acquisition Disposition of Subsidiaires--------436M-120M
Increase (Decrease) in Investments81M-67M-104M5M42M337M322M252M-197M16M
Other Cash Inflow (Outflow) from Investment Activities-2M-21M-20M-4M-4M-433M-410M-416M-62M-24M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares------242M-231M-236M-232M-
Issuance (Repayment) of Debt Securities-290M297M291M293M-80M-77M-1M--177M
Increase (Decrease) in Bank & Other Borrowings23M-277M-194M-229M-268M332M420M401M52M-4M
Payment of Dividends & Other Cash Distributions--61M-63M-61M--52M-50M-51M--62M
Other Cash from (used by) Financing Activities-5M-20M-15M-10M-5M-14M-8M-5M-2M-14M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-1M---1M-8M-5M-5M-1M-65M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year37M58M76M81M136M84M135M111M147M120M
Cash & Equivalents at Year End32M39M30M37M44M59M89M35M94M74M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Dr. Reddy's Laboratories stock comparison chart provides an easy way to compare the stock price with peers along with details of Dr. Reddy's Laboratories stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Dr. Reddy's Laboratories had a Net Change in Cash and Cash Equivalents of $-5M in the latest quarter 2019 Q1. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Dr. Reddy's Laboratories stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Dr. Reddy's Laboratories lost $-73M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: Dr. Reddy's Laboratories generated $51M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $17M for Dr. Reddy's Laboratories.

Key Financial Ratios For Dr. Reddy's Laboratories Cash Flow

FCF margin

Quarterly Cash Flow Statements For Dr.Reddy's Laboratories Ltd (ADR) Peers

ASPEN PHARMACR cash flow, BAUSCH HEALTH cash flow, Novartis cash flow, Sanofi cash flow, Teva Pharmaceutical cash flow